Paper7688656
Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol.
Bruchovsky N and 3 others. Cancer, 1993. Cited by 38 papers, by iCite.
Cite this record
ConductScience Library. Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol. Papers, record 7688656. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7688656
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics22
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cyproterone Acetate | Major topic |
| Diethylstilbestrol | Major topic |
| Goserelin | Major topic |
| Prostatic Neoplasms | Major topic |
| Acid Phosphatase | |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Follicle Stimulating Hormone | |
| Gonadotropin-Releasing Hormone | |
| Humans | |
| Luteinizing Hormone | |
| Male | |
| Middle Aged | |
| Neoplasm Staging | |
| Pilot Projects | |
| Pituitary Gland | |
| Prostate | |
| Prostate-Specific Antigen | |
| Remission Induction | |
| Survival Rate | |
| Testosterone |
Source PubMed
Cited by15
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 38 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 29624800 | Efficacy and safety of 3-month dosing regimen of degarelix in Japanese subjects with prostate cancer: A phase III study. | Cancer Sci | 2018 | https://conductscience.org/library/papers/29624800 | PubMed |
| 16986003 | Flare Associated with LHRH-Agonist Therapy. | Rev Urol | 2001 | https://conductscience.org/library/papers/16986003 | PubMed |
| 16985931 | Challenges with luteinizing hormone-releasing hormone agonists: flare and surge. | Rev Urol | 2004 | https://conductscience.org/library/papers/16985931 | PubMed |
| 16896883 | What implications do the tolerability profiles of antiandrogens and other commonly used prostate cancer treatments have on patient care? | J Cancer Res Clin Oncol | 2006 | https://conductscience.org/library/papers/16896883 | PubMed |
| 15161573 | Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer. | Curr Urol Rep | 2004 | https://conductscience.org/library/papers/15161573 | PubMed |
| 14727892 | Evaluation of Orntide microspheres in a rat animal model and correlation to in vitro release profiles. | AAPS PharmSciTech | 2000 | https://conductscience.org/library/papers/14727892 | PubMed |
| 12941195 | Adjuvant hormone therapy after radiation or surgery for localized or locally advanced prostate cancer. | Curr Treat Options Oncol | 2003 | https://conductscience.org/library/papers/12941195 | PubMed |
| 11057778 | 'Hot flush', an unpleasant symptom accompanying antiandrogen therapy of prostatic cancer and its treatment by cyproterone acetate. | Int Urol Nephrol | 2000 | https://conductscience.org/library/papers/11057778 | PubMed |
| 10871814 | Prostate cancer: a comprehensive review. | Med Oncol | 2000 | https://conductscience.org/library/papers/10871814 | PubMed |
| 10870989 | Effect of the concurrent LHRH antagonist administration with a LHRH superagonist in rats. | Pharm Res | 2000 | https://conductscience.org/library/papers/10870989 | PubMed |
| 10408706 | Controversies in the management of advanced prostate cancer. | Br J Cancer | 1999 | https://conductscience.org/library/papers/10408706 | PubMed |
| 9951446 | Prostate cancer: 9. Treatment of advanced disease. | CMAJ | 1999 | https://conductscience.org/library/papers/9951446 | PubMed |
| 9241550 | Cyproterone acetate monotherapy in advanced prostatic carcinoma. | Int Urol Nephrol | 1997 | https://conductscience.org/library/papers/9241550 | PubMed |
| 7919640 | Cyproterone. A review of its pharmacology and therapeutic efficacy in prostate cancer. | Drugs Aging | 1994 | https://conductscience.org/library/papers/7919640 | PubMed |
| 7533693 | Prospects for pharmacological male contraception. | Drugs | 1994 | https://conductscience.org/library/papers/7533693 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| KLK3 | 354 | PubTator's text mining | https://conductscience.org/library/genes/354 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/7688656
GET https://conductscience.org/api/papers/v1/7688656/authors